Roche

[키워드] 1:1 24 hour acute respiratory distress Administered administration Aerogen Aerogen Solo® Aerosols age airway alveolar alveolar injury anticipated ARDS backbone Berlin criteria blinded blocker Breastfeeding carrier cell-free DNA citrullinated histones clearance cleave Clinical practice clinical trial comparator Compound computer-generated consecutive patient control arm coronavirus 2 coronavirus disease COVID-19 COVID-19 patients criteria damage-associated molecular pattern DAMP DAMPs diagnosed with COVID-19 dissemination distal Dornase alfa dose double-stranded DSMB Efficacy element eliminated enteral nutrition Extracellular extracellular DNA fibrosis glycemic control hospital Hospitalized hospitals hyperinflammation hypersensitivity ICU Inclusion inclusion criteria induce Inflammation intensive care interim analysis Intervention Ireland less looser lung lung damage Lungs management mechanical ventilation mechanically ventilated patient monitoring board myeloperoxidase NET NETs neutrophil Neutrophil extracellular trap Neutrophil extracellular traps number objective Occurrence Open-label outcome PaO Paris participant Patient patients PEEP performed Pneumocytes Primary outcome progression Prone position Protective protocol randomisation randomised randomised controlled trial Randomized receive recruit recruitment reduce reducing Registered respiratory Roche Rothschild Sample size SARS-CoV-2 secretion Sedation Severe COVID-19 pneumonia severe pneumonia severity statistical analysis status study group Study protocol Switzerland syndrome to define Toxicity tracheal Treatment Trial usual care Ventilation vibrating mesh nebulizer Volume website
[DOI] 10.1186/s13063-020-04488-8 PMC 바로가기 [Article Type] Letter